European Oncolytic Virus Therapy Market Opportunity, Size, Share and Forecast 2019-2025

The European oncolytic virus therapy market is estimated to grow at a CAGR of around 14% during the forecast period. The market growth is attributed to the increasing number of clinical trials in the region coupled with the increasing prevalence of cancer in the region, thereby creating opportunities for the growth of the market. The market growth in Europe is attributed to the FDA approval for the commercialization of Imlygic in Europe in 2016. Moreover, there are numerous clinical trials that are still being conducted across the region.

Request a Free Sample of our Report on European Oncolytic Virus Therapy Market: https://www.omrglobal.com/request-sample/european-oncolytic-virus-therapy-market

Further, the European oncolytic virus therapy market is segmented on the basis of product and application. Based on the product, the market is segmented into HSV-based oncolytic viruses, adenoviruses-based oncolytic viruses, vaccinia virus-based oncolytic viruses, vesicular stomatitis virus-based oncolytic viruses, Newcastle disease oncolytic viruses, and other oncolytic viruses. HSV-based oncolytic virus therapy held the highest market share in 2018. Based on the application, the market is segmented into prostate cancer, breast cancer, ovarian cancer, melanoma, and others. In 2018, the melanoma application held the largest market share.

The report covers the analysis of several players operating in the European oncolytic virus therapy market. Some of the major players include Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Medigene AG, Orca Therapeutics, OncoTheis, and others. In March 2018, Medigene AG started phase I/II clinical trial CD-TCR-001 (NCT03503968) with TCR-T cell immunotherapy MDG1011 for the treatment of various types of blood cancer. The MDG1011 is a company's first clinical TCR-T immunotherapy product candidate, with its first clinical trial with a TCR-T therapy in Germany. The phase I/II trial investigates the safety of MDG1011 to treat various types of blood cancer, which include acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM).

A Full Report of European Oncolytic Virus Therapy Market is Available at https://www.omrglobal.com/industry-reports/european-oncolytic-virus-therapy-market

European Oncolytic Virus Therapy Oncolytic Virus Therapy Market Segmentation

By Product
o HSV-Based Oncolytic Virus
o Adenoviruses-Based Oncolytic Virus
o Vaccinia Virus-Based Oncolytic Virus
o Vesicular Stomatitis Virus-Based Oncolytic Virus
o Newcastle Disease Virus- Based Oncolytic Virus
o Others

By Application
o Prostate Cancer
o Breast Cancer
o Ovarian Cancer
o Melanoma
o Others

Regional Analysis
o UK
o Germany
o Italy
o Spain
o France
o Rest of Europe

Company Profiles
o Oncolys BioPharma Inc.
o Otsuka Pharmaceuticals Co. Ltd.
o Shanghai Sunway Biotech Co., Ltd.
o SillaJen, Inc.
o Takara Bio Inc.
o Viralytics Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/european-oncolytic-virus-therapy-market

For More Information, Visit https://www.omrglobal.com/

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 780-304-0404

About us:

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.